These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26900637)

  • 1. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of Discontinuation of Efavirenz as Treatment for HIV, Due to Neuropsychiatric Side Effects, in a Multi-Ethnic Sample in the United Kingdom.
    Law JKC; Butler LT; Hamill MM
    AIDS Res Hum Retroviruses; 2020 Jun; 36(6):459-466. PubMed ID: 31931589
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
    Gazzard B; Balkin A; Hill A
    AIDS Rev; 2010; 12(2):67-75. PubMed ID: 20571601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A systematic review of the psychiatric side-effects of efavirenz.
    Kenedi CA; Goforth HW
    AIDS Behav; 2011 Nov; 15(8):1803-18. PubMed ID: 21484283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
    Ahmadi M; Khalili H; Abbasian L; Ghaeli P
    Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
    Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
    Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of dizziness in human immunodeficiency virus-infected patients taking zidovudine and efavirenz combination: a Brazilian cohort study.
    Valeriano JJLS; Carvalho-Silva WHV; Coelho AVC; Moura RR; Arraes LC; Brandão LAC; Crovella S; Guimarães RL
    J Pharm Pharmacol; 2020 May; 72(5):719-727. PubMed ID: 32043598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.
    Dabaghzadeh F; Khalili H; Ghaeli P; Dashti-Khavidaki S
    Expert Opin Pharmacother; 2012 Dec; 13(18):2613-24. PubMed ID: 23140169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial.
    Dabaghzadeh F; Ghaeli P; Khalili H; Alimadadi A; Jafari S; Akhondzadeh S; Khazaeipour Z
    AIDS Patient Care STDS; 2013 Mar; 27(3):146-54. PubMed ID: 23442031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
    Poupard M; Ngom Gueye NF; Thiam D; Ndiaye B; Girard PM; Delaporte E; Sow PS; Landman R
    HIV Med; 2007 Mar; 8(2):92-5. PubMed ID: 17352765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of Depression and Anxiety After Discontinuation of Long- Term Efavirenz Treatment.
    Mothapo KM; Schellekens A; van Crevel R; Keuter M; Grintjes-Huisman K; Koopmans P; van der Ven A
    CNS Neurol Disord Drug Targets; 2015; 14(6):811-8. PubMed ID: 25808896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of side effects with 2 doses of the HIV drug efavirenz.
    Ann Intern Med; 2009 Aug; 151(3):I24. PubMed ID: 19581632
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efavirenz and the CNS: what we already know and questions that need to be answered.
    Apostolova N; Funes HA; Blas-Garcia A; Galindo MJ; Alvarez A; Esplugues JV
    J Antimicrob Chemother; 2015 Oct; 70(10):2693-708. PubMed ID: 26203180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuropsychiatric complications of efavirenz therapy: suggestions for a new research paradigm.
    Sütterlin S; Vögele C; Gauggel S
    J Neuropsychiatry Clin Neurosci; 2010; 22(4):361-9. PubMed ID: 21037119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Neurospychiatric symptoms in HIV infected patients and the role of efavirenz].
    Bary M; David F; Gasnault J; Kerneis H; Linard F; Longuet P; Pelissolo A; Ravaux I
    Med Mal Infect; 2004 Oct; 34(10):435-49. PubMed ID: 15747468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses].
    Hinsch MC; Reichelt D; Husstedt IW
    Nervenarzt; 2014 Oct; 85(10):1304-8. PubMed ID: 25200885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maximizing Knowledge Extraction From Patient-Reported Outcome Data Using Exposure-Outcome Item Response Modeling Approach: Understanding Efavirenz-Induced Central Nervous System Toxicity.
    Bisaso KS; Bisaso KR; Mukonzo JK; Ette EI
    J Clin Pharmacol; 2020 Jun; 60(6):711-721. PubMed ID: 32096561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.